IMPACT Study Showed Longer Valcyte (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

Links shared publicly online about this topic.

2,001
total visits

IMPACT Study Showed Longer Valcyte (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ("prophylaxis') with Valcyte (oral valganciclovir) significantly reduced the incidence of CMV disease by 56% in high-risk kidney transplant patients within the first year post-transplant.

View full resource at newswise.com

Tags: Kidney Health, Urinary System, Organ Transplantation, Kidney Transplant, Disease and Condition, Transplantation, disease